Form 4: Tenet Healthcare Officer Sells Shares, Receives New RSU Grant

Thomas W. Arnst, EVP, Chief Admin. Officer & GC of Tenet Healthcare Corp, reported significant stock transactions including RSU vesting, tax-related dispositions, and a substantial sale of common stock.

Summary

• Thomas W. Arnst, EVP, Chief Admin. Officer & GC, reported multiple transactions in Tenet Healthcare Corp (THC) common stock and restricted stock units (RSUs).
• On February 27, 2026, Arnst acquired 5,604 shares and 5,598 shares of common stock through the vesting of restricted stock units.
• On the same date, he disposed of 1,496 shares (at $237.58), 4,409 shares (at $239.39), and 14,870 shares (at $239.39) to satisfy tax withholding obligations upon the vesting of performance share units and restricted stock units.
• On March 2, 2026, Arnst sold 24,000 shares of common stock at a weighted average price of $234.04, with individual sales ranging from $234.00 to $234.34.
• Following these transactions, Arnst's direct beneficial ownership of common stock decreased to 8,012 shares.
• Arnst also received a new grant of 7,520 time-based restricted stock units on February 27, 2026, which will vest in one-third increments over three years.
• The second one-third increment of 5,604 restricted stock units from a February 28, 2024 grant vested on February 27, 2026.
• The third one-third increment of 5,598 restricted stock units from a March 1, 2023 grant vested on February 27, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The executive received new equity awards and vested shares, but also sold a significant portion of common stock, likely for personal financial planning and tax purposes, which is typical for insider transactions.

Positives

• Receipt of a new grant of 7,520 time-based Restricted Stock Units on February 27, 2026, indicating continued long-term incentive for the executive.
• Vesting of 5,604 Restricted Stock Units from the 2024 grant and 5,598 Restricted Stock Units from the 2023 grant, converting into common stock.

Negatives

• Significant sale of 24,000 shares of common stock on March 2, 2026, at a weighted average price of $234.04.
• Disposition of 20,775 shares (1,496 + 4,409 + 14,870) to cover tax withholding obligations upon vesting of performance share units and restricted stock units.
• A substantial reduction in direct beneficial ownership of common stock from 52,787 shares (before the large sale and tax dispositions) to 8,012 shares after all reported transactions.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, are common occurrences in publicly traded companies. While a sale by an executive can sometimes be interpreted negatively, it often relates to personal financial planning, diversification, or tax obligations, especially following the vesting of equity awards. The grant of new RSUs indicates continued alignment of executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The sale of shares by a high-ranking executive could be perceived negatively by some, but the simultaneous grant of new RSUs aligns the executive's long-term interests with shareholder value. The overall impact is likely neutral given the routine nature of such transactions.

Next Steps

• The newly granted 2026 February Restricted Stock Units will vest in one-third increments on the first, second, and third anniversaries of the grant date (February 27, 2026).

Key Dates

Recommendation

The filing details routine insider transactions, including the vesting of equity awards, tax-related dispositions, and a subsequent sale of common stock by a key executive. While the sale is substantial, it is balanced by the grant of new restricted stock units, indicating ongoing executive alignment. These transactions are typical for executive compensation and personal financial management and do not suggest a fundamental change in the company's prospects or the executive's confidence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information warranting a change in investment thesis.

Keywords

Tenet Healthcare, THC, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Executive Compensation, Thomas W. Arnst, Officer Transaction